Alivus Life Sciences Limited (BOM:543322)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018
Active Pharmaceutical Ingredient (API)	25.52B	23.87B	22.83B	21.61B	21.23B
Active Pharmaceutical Ingredient (API) Growth	6.91%	4.54%	5.64%	1.79%	12.63%
Total	25.52B	23.87B	22.83B	21.61B	21.23B
Total Growth	6.91%	4.54%	5.64%	1.79%	12.63%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018
India	11.52B	11.66B	11.33B	11.52B
India Growth	-1.21%	2.95%	-1.64%	9.91%
outside India	12.35B	11.17B	10.28B	9.71B
outside India Growth	10.55%	8.61%	5.86%	16.04%
Total	23.87B	22.83B	21.61B	21.23B
Total Growth	4.54%	5.64%	1.79%	12.63%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 10, 2026

Data Sources Report a data error